Artera Receives California Lab License, Expanding Access to its ArteraAI Prostate Test

Clinicians and patients in California can now access personalized, actionable insights to inform prostate cancer treatment decisions

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today it has received its California laboratory license from the California Department of Public Health (CDPH). This licensure allows Artera to offer its innovative ArteraAI Prostate Test to one of the largest healthcare markets in the United States.

The ArteraAI Prostate Test is the first test that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer. Starting October 10, 2024 clinicians and patients in California can access data-backed insights to personalize cancer treatment decisions.

“Receiving the California lab license is a significant milestone for Artera, allowing us to serve more patients and clinicians across the U.S.,” said Andre Esteva, CEO and co-founder of Artera. "Prostate cancer is one of the most common cancers in American men, and the American Cancer Society estimates more than 26,000 men will be diagnosed with prostate cancer in California alone. Our goal is to provide easy and convenient access to AI-powered precision medicine, providing individuals with better insights and clarity in their treatment decisions.”

This license follows the College of American Pathologists (CAP) accreditation Artera received in August this year. During the CAP accreditation process, CAP inspectors examine laboratory staff qualifications, equipment, facilities, safety program, record, and overall management to ensure the highest standard of care for all laboratory patients. Together, these certifications underscore Artera’s commitment to quality and patient safety.

“We are excited the ArteraAI Prostate Test is now available in California, especially given that much of the initial development of the MMAI biomarker took place here at UCSF,” said Peter Carroll, MD, MPH, Professor of Urology at the University of California, San Francisco. “Artera’s predictive biomarker recognized in national guidelines for localized prostate cancer has the potential to significantly empower treatment decisions, including patients considering androgen deprivation therapy (ADT) in combination with radiation. Both clinicians and patients deserve access to innovative, extensively validated technologies like this to ensure the highest level of personalized and optimal care.”

About Artera

Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test.

Artera’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials.

ArteraAI Prostate Test is the first test that can both prognosticate long-term outcomes and predict therapy benefit in localized prostate cancer.

Artera’s laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera’s laboratory in Jacksonville, Florida, and can be ordered online at Artera.ai.